Our Cigna Specialty Care Options^SM (SCO) and Cigna Specialty Care Options Plus^SM (SCO+) programs identify customers whose nononcology and oncology specialty medications are being administered in a higher-intensity setting (e.g., outpatient hospital) to determine whether a less-intensive site of care is clinically appropriate. These customers are identified at the time of prior authorization.

The SCO and SCO+ programs contain a medical necessity site-of-care review for select oncology products in accordance with our Medication Administration Site of Care coverage policy.

When clinically appropriate, we redirect customers to a quality, less-intensive site of care, such as a contracted provider’s office, a customer’s home with infusion nurses, or a non-hospital-based ambulatory infusion center. In certain circumstances, procurement from a specialty pharmacy with which we have a reimbursement arrangement may be an option.

SCO and SCO+ drug list expansion

We recently expanded the SCO and SCO+ drug lists to include the specialty medical injectables listed below.

SCO and SCO+ drug list

To access the SCO and SCO+ drug list, log in to the Cigna for Health Care Professionals website (CignaforHCP.com) > Resources > Reimbursement and Payment Policies > Precertification Policies > Specialty Care Options and Specialty Care Options Plus Drug List. We recommend you review this list frequently, as it is subject to change. Specialty medical injectables may be added upon U.S. Food & Drug Administration approval.